PLRX on Nasdaq

Pliant (United States)

We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics.1

Price unavailable

Last updated Oct 19, 2026.

Overview

2016Founded1

Compare with Rani Therapeutics Holdings, Inc., CYPHERPUNK TECHNOLOGIES INC. or Cleveland BioLabs, or pick any stock.

  • TickerPLRX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSouth San Francisco, California1
  • Websitepliantrx.com
  • Incorporated inDE3
  • Business address331 Oyster Point Boulevard, South San Francisco, Ca 940803
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Our lead program is focused on the development of treatments for solid tumors by inhibiting integrin-mediated activation of transforming growth factor-β (TGF-β). We have applied our deep understanding of integrin biology, along with our medicinal chemistry and translational medicine expertise to develop a proprietary drug discovery platform that we believe has broad applicability across multiple areas of disease.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-82.4%Return on equity5
0.00×Debt to equity5
-$128.7MFree cash flow5

Financial statements

Revenue6785$0 in 2025
0$20.0M$40.0M$60.0M2019: $57.1M$57.1M20192020: $41.8M$41.8M2020−27%2021: $7.6M$7.6M2021−82%2022: $9.7M$9.7M2022+28%2023: $1.6M$1.6M2023−84%2024: $0$020242025: $0$02025
Operating income6785-$156.4M in 2025+12603% since 2019
-$300.0M-$200.0M-$100.0M02019: -$1.2M-$1.2M20192020: -$41.6M-$41.6M2020+3283%2021: -$97.5M-$97.5M2021+134%2022: -$127.2M-$127.2M2022+30%2023: -$184.1M-$184.1M2023+45%2024: -$228.4M-$228.4M2024+24%2025: -$156.4M-$156.4M2025−32%
Net income6785-$149.3M in 2025+23568% since 2019
-$300.0M-$200.0M-$100.0M02019: -$631.0K-$631.0K20192020: -$41.5M-$41.5M2020+6482%2021: -$97.3M-$97.3M2021+134%2022: -$123.3M-$123.3M2022+27%2023: -$161.3M-$161.3M2023+31%2024: -$210.3M-$210.3M2024+30%2025: -$149.3M-$149.3M2025−29%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue$0$0
Research and development-$109.2M-$169.3M
General and administrative-$47.2M-$59.1M
Total operating expenses-$156.4M-$228.4M
Loss from operations-$156.4M-$228.4M
Interest and other income (expense), net$11.4M$21.1M
Interest expense-$2.6M-$3.0M
Loss on extinguishment of debt (Note 7)-$1.8M$0
Net loss-$149.3M-$210.3M
Net loss per share - basic (USD per share)-$2.43-$3.47
Net loss per share - diluted (USD per share)-$2.43-$3.47
Weighted average shares used in computing net loss per share - basic (in shares)61.4M shares60.5M shares
Weighted average shares used in computing net loss per share - diluted (in shares)61.4M shares60.5M shares
Net unrealized loss on short-term investments-$336.0K-$24.0K
Total other comprehensive loss-$336.0K-$24.0K
Comprehensive loss-$149.7M-$210.3M

Compare Pliant (United States) with another company

Leadership

Who has led Pliant (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Bernard Coulie2020–now

President

  1. Bernard Coulie2020–now

Chief operating officer

  1. Minnie Kuo2025–now
20202025
Board members and other officers (20)

Timeline

  1. Jun 2, 2020New chief executive Bernard Coulie becomes CEO13
  2. 2016Founded Founded1

Filings

324 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 58 major events, 158 insider forms, 47 large holders, 39 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Oct 2, 20263 EDGAR
  3. Aug 14, 2026SCHEDULE 13G EDGAR
  4. Aug 14, 2026SCHEDULE 13G/A EDGAR
  5. Aug 11, 20268-K EDGAR
  6. Aug 11, 202610-Q EDGAR
  7. Jul 13, 20263 EDGAR
  8. Jul 13, 20264 EDGAR
  9. Jul 13, 20268-K EDGAR
  10. Jul 13, 20263 EDGAR
  11. Jul 13, 20264 EDGAR
  12. Jun 12, 20264 EDGAR
  13. Jun 12, 20264 EDGAR
  14. Jun 12, 20264 EDGAR
  15. Jun 12, 20264 EDGAR
  16. Jun 12, 20264 EDGAR
  17. Jun 12, 20264 EDGAR
  18. Jun 11, 20268-K EDGAR
  19. May 11, 202610-Q EDGAR
  20. May 11, 20268-K EDGAR

The 324 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

63 open-market trades by officers, directors and large owners since October 2021: 0 buys and 63 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 20, 2026Cummings Keith LamontChief Financial OfficerSale24,002$1.28$30.7KForm 4
Jan 20, 2026Cheung LilyChief Human Resource OfficerSale7,534$1.28$9.6KForm 4
Jan 20, 2026Coulie BernardPresident and CEOSale89,375$1.28$114.4KForm 4
Jan 20, 2026Kuo MinnieChief Operating OfficerSale6,917$1.28$8.9KForm 4
Jan 22, 2025Ouimette MikeGeneral Counsel & Corp. Sec'ySale10,230$10.99$112.4KForm 4
Jan 17, 2025Coulie BernardPresident and CEOSale52,419$11.20$587.1KForm 4
Jan 17, 2025Cummings Keith LamontChief Financial OfficerSale20,148$11.20$225.7KForm 4
Jan 17, 2025Hull HansChief Business OfficerSale15,936$11.20$178.5KForm 4
Jan 17, 2025Lefebvre EricChief Medical OfficerSale18,478$11.20$207.0KForm 4
Jan 17, 2025Cheung LilyChief Human Resource OfficerSale3,740$11.20$41.9KForm 4
Jan 17, 2025Ouimette MikeGeneral Counsel & Corp. Sec'ySale13,270$11.20$148.6KForm 4
Jul 10, 2024Lefebvre EricChief Medical OfficerSale12,319$11.56$142.4KForm 4
Jul 10, 2024Hull HansChief Business OfficerSale9,900$11.56$114.4KForm 4
Jul 10, 2024Cummings Keith LamontChief Financial OfficerSale10,911$11.56$126.1KForm 4
Jul 10, 2024Coulie BernardPresident and CEOSale38,710$11.56$447.5KForm 4
Jul 10, 2024Ouimette MikeGeneral Counsel & Corp. Sec'ySale7,656$11.56$88.5KForm 4
Jan 17, 2024Cummings Keith LamontChief Financial OfficerSale9,781$17.23$168.5KForm 4
Jan 17, 2024Hull HansChief Business OfficerSale9,786$17.23$168.6KForm 4
Jan 17, 2024Coulie BernardPresident and CEOSale25,721$17.23$443.2KForm 4
Jan 17, 2024Lefebvre EricChief Medical OfficerSale10,295$17.23$177.4KForm 4

All 63 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 85. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Tang Capital Management LLC6,141,261$7.0M0.3%−1,871
ADAR1 Capital Management, LLC5,509,724$6.3M0.3%+2,924,598
Vanguard Capital Management LLC2,440,351$2.8M0.0%+97,250
Two Sigma Investments, LP2,262,832$2.6M0.0%+9,694
Citadel Advisors LLC2,142,226$2.4M0.0%−1,084,373
Renaissance Technologies LLC2,049,874$2.3M0.0%+197,032
Monaco Asset Management SAM1,938,747$2.2M0.8%No change
Lynx1 Capital Management LP1,798,070$2.0M0.2%New
BML Capital Management, LLC1,546,137$1.8M1.0%No change
Prosight Management, LP1,370,233$1.6M0.3%−297,367
Peapod Lane Capital LLC1,309,013$1.5M1.0%+20,435
Woodline Partners LP1,296,534$1.5M0.0%−370,296
BlackRock, Inc.1,151,214$1.3M0.0%+54,784
Ikarian Capital, LLC1,000,000$1.1M0.2%New
Eversept Partners, LP891,425$1.0M0.1%No change
Marshall Wace, Llp835,124$952.0K0.0%−160,849
Redmile Group, LLC772,126$880.2K0.1%No change
Jpmorgan Chase & Co681,647$783.9K0.0%−180,176
Jacobs Levy Equity Management, Inc643,120$733.2K0.0%−75,423
Geode Capital Management, LLC578,577$660.0K0.0%+161,303
UBS Group AG571,760$651.8K0.0%−486,194
Millennium Management LLC559,447$637.8K0.0%−621,071
Bridgeway Capital Management, LLC553,630$631.1K0.0%No change
Connor, Clark & Lunn Investment Management Ltd.536,081$611.1K0.0%+18,628
DAFNA Capital Management LLC487,000$555.2K0.1%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52